Programmed death ligand 1 and CD8+ immune cell infiltrates in resected primary tracheal malignant neoplasms | Zendy

Luis F. Tapias | Zendy; Angela Shih | Zendy; Mari MinoKenudson | Zendy; Ashok Muniappan | Zendy; Henning A. Gaissert | Zendy; Michael Lanuti | Zendy; Douglas J. Mathisen | Zendy; Harald C. Ott | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Programmed death ligand 1 and CD8+ immune cell infiltrates in resected primary tracheal malignant neoplasms

Author(s) -

Luis F. Tapias,

Angela Shih,

Mari MinoKenudson,

Ashok Muniappan,

Henning A. Gaissert,

Michael Lanuti,

Douglas J. Mathisen,

Harald C. Ott

Publication year - 2018

Publication title -

european journal of cardio-thoracic surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.303

H-Index - 133

eISSN - 1873-734X

pISSN - 1010-7940

DOI - 10.1093/ejcts/ezy370

Subject(s) - pathology , medicine , mucoepidermoid carcinoma , immune system , cd8 , adenosquamous carcinoma , immunohistochemistry , adenoid cystic carcinoma , malignancy , adenoid , carcinoma , adenocarcinoma , cancer , immunology

Many patients with primary malignant tracheal neoplasms are not surgical candidates nor do they experience residual or recurrent disease after surgery and may benefit from alternative therapies. This study explores the expression of programmed death ligand 1 (PD-L1) in patients with primary tracheal malignancy as a biomarker for candidacy for treatment with immune checkpoint inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research